ReviewJournal of gynecologic oncology2017
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Review in Journal of gynecologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A novel ex vivo platform for functional evaluation of treatment responses in metastatic ovarian cancer.NPJ precision oncology · 2026Article
- Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.The oncologist · 2025Review
- Divergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database.Obstetrics and gynecology international · 2025Article
- Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.British journal of cancer · 2024Article
- From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.Journal of ovarian research · 2024Review
- Endometriosis and epithelial ovarian cancer: a two-sample Mendelian randomization analysis.Scientific reports · 2023Article
- Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma.Frontiers in oncology · 2022Article
- Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.OncoTargets and therapy · 2022Article
- Review
- Precision medicine for ovarian clear cell carcinoma based on gene alterations.International journal of clinical oncology · 2020Review
- Mucinous Cancer of the Ovary: Overview and Current Status.Diagnostics (Basel, Switzerland) · 2020Review
- Article
- Urachal Mucinous Cystic Tumor of Low Malignant Potential with Concurrent Sigmoid Colon Adenocarcinoma.Case reports in gastrointestinal medicine · 2019Article
- Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.